In this exclusive video from DDW 2016, Mark Pochapin, MD, from NYU Langone Medical Center, discusses Gastro Girl, a new online platform that provides support to patients with chronic gastrointestinal symptoms and conditions.
It’s no secret that one of the biggest things holding New York City’s biotech ecosystem back is lack of lab space for startups. The problem will take a broad effort to solve, not just a few buildings or incubators. But one of the city’s biggest real estate players, Alexandria Real Estate Equities, has announced a plan today to help out.
The Maryland Department of Commerce is joining with the state’s top research universities and other life sciences partners and stakeholders to create two or more Centers of Excellence around the state to support cell, gene and regenerative therapies, as well as medical devices and 3-D printing. This partnership with The Johns Hopkins University, the University of Maryland, Baltimore and the University of Maryland, College Park will help position Maryland as a leader in commercialization and clinical translation of next-generation medicines and medical devices and ensure the state remains a leader in healthcare innovation. Additional partners include the Center for Medical Technology Policy and biotechnology, pharmaceutical, contract manufacturing, and medical device companies.
Gaithersburg-based Novavax Inc. plans to create up to 850 new jobs as part of its planned Montgomery County expansion and will receive state and county financial assistance to support the growth, it was announced Wednesday.
The next Kendall Square just might be located in Allston.
The gritty Boston neighborhood, across the Charles from Harvard University’s main campus, is the site of various construction projects aimed at building up an innovation epicenter over the next five to 10 years. Just don’t tell Jodi Goldstein about the Kendall comparison.
Longitude Capital, an investment firm focused on venture growth investments in biotechnology and medical technology, closed its third fund, at $525m in partner commitments.
The Kansas City, Mo.-based Kauffman Foundation recently released its 2016 Kauffman Index of Growth Entrepreneurship and found — to the authors seeming surprise — that the Washington, D.C. metro area topped a list of U.S. metro areas with the most growth entrepreneurship.
Three experts explain synthetic biology and discuss its potential to affect fields as varied as medicine, oil, agriculture, and even fragrances.
Can you tell us a bit about your background?
I trained as a physician and scientist, having received both an MD and a PhD. I did my residency in pathology and about 11 years ago I decided to make the transition from academia to industry. Since then, most of my work has been focused on immunotherapy, which is a new and very exciting area of cancer research. Nine months ago I joined MedImmune, the global biologics arm of AstraZeneca, as the head of oncology development.
The cover of Ernst & Young’s 2016 biotech report has a picture of a parachutist and the subtitle, “Returning to Earth.” According to EY, the biotech industry has experienced explosive growth over the past few years, but that appears to have slowed in 2015. On its own, a 13 percent increase in biotech revenue looks impressive – unless it’s compared to the 18 percent increase in 2014.